63625-94-5

Basic information

• Product Name: ethyl 3,4-dihydronaphthalen-2-ylacetate
• CAS NO: 63625-94-5
• Molecular Formula: C₁₄H₁₆O₂
• Molecular Weight: 216.2756
• Mol File: 63625-94-5.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 317.3°C at 760 mmHg
• Flash Point: 132.2°C
• Density: 1.072g/cm³
• Vapor Pressure: 0.000389mmHg at 25°C
• Refractive Index: 1.537
• CAS DataBase Reference: ethyl 3,4-dihydronaphthalen-2-ylacetate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 3,4-dihydronaphthalen-2-ylacetate(63625-94-5)
• EPA Substance Registry System: ethyl 3,4-dihydronaphthalen-2-ylacetate(63625-94-5)

Safety Data

• Hazardous Substances Data: 63625-94-5(Hazardous Substances Data)

Upstream product

• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 530-93-8 1,2,3,4-tetrahydronaphthalen-2-one 
• 154935-59-8 2-ethoxycarbonylmethyl-1,2,3,4-tetrahydronaphthalen-2-ol 

Downstream Products

• 91524-14-0 Napamezole 

Relevant articles and documents

Catalytic Enantioselective Bromoaminocyclization and Bromocycloetherification

We apply a chiral anionic phase-transfer system for the catalytic asymmetric bromoaminocyclization and bromocycloetherification of momo-functional benzo-cyclic alkenes. Various brominated tricyclic benzo-heterocycles were produced with up to 99% yields and 99% enantiomeric excess. The resulting enantioenriched hexahydro-benzoindoles are key building blocks of bioactive molecules. (Figure presented.).

Amination of arenes through electron-deficient reaction cascades of aryl epoxyazides

(Matrix presented) Aryl epoxyazides undergo efficient electron-deficient reaction cascades mediated by Lewis acids, leading to regiospecific amination of the aromatic ring.

Potential antidepressants displayed combined α2-adrenoceptor antagonist and monoamine uptake inhibitor properties

Classical antidepressants are thought to act by raising monoamine (serotonin and noradrenaline) levels in the brain. This action is generally accomplished either by inhibition of monoamine metabolism (MAO inhibitors) or by blockade of monoamine uptake (tricyclic antidepressants and selective serotonin or noradrenaline reuptake inhibitors). However, all such agents suffer from a time lag (3-6 weeks) before robust clinical efficacy can be demonstrated. This delay may reflect inhibitory actions of noradrenaline at presynaptic α2A-adrenergic auto- or heteroreceptors which gradually down-regulate upon prolonged exposure. Blockade of presynaptic α2A-adrenoceptors by an antagonist endowed with monoamine uptake inhibition properties could lead to new antidepressants with greater efficacy and a shorter time lag. In the literature, only two molecules-have been described with such a pharmacological profile. Of these, napamezole (2) was chosen as a point of departure for the design of 4(5)-[(3,4-dihydro-2-naphthalenyl)methyl]-4,5-dihydroimidazole (4a), which displayed the desired profile: α2A-adrenoceptor antagonist properties and serotonin/noradrenaline uptake inhibition. From this original molecule, a series of derivatives was designed and synthesized, encompassing substituted as well as rigid analogues. Structure-activity relationships permitted the selection of 14c (4(5)-[(5-fluoroindan-2-yl)methyl]-4,5-dihydroimidazole) as a development candidate.